United Therapeutics Corporation (NASDAQ:UTHR)
About United Therapeutics Corporation (NASDAQ:UTHR) United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases. The Companyâ€™s principal therapeutic platforms include Prostacyclin Analogs, Phosphodiesterase Type 5 (PDE5) inhibitors, Monoclonal Antibodies and Glycobiology Antiviral Agents. Prostacyclin Analogues are stable synthetic forms of prostacyclin. Its lead product is Remodulin (treprostinil) Injection (Remodulin) to be administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension (PAH). The Companyâ€™s PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of PAH. The Company is developing the antibodies 3F8 MAb and 8H9 MAb for the treatment of neuroblastoma and metastatic brain cancer, respectively.
52 week range
Financials United Therapeutics Corporation (NASDAQ:UTHR) generated total revenue of $170.98 million in current quarter which is 20.25 percent greater than last quarter’s ending. Moreover, operating and net income both have increased considerably which is a strong sign, they produced better result as compared last quarter’s ending. The company’s cash flow from operation stood at $172.28 million as contrasted to last quarter’s cash flow from operation which was placed at $69.45 million. CFOin current quarter is positive which shows that the company generated more cash than its expensesfor the current quarter. The company’s total assets accumulate up to $1.28 billion as per its latest financials as on September 30, 2010. Fixed assets claim to have the highest contribution in the total assets. The company’s total liabilities and equity build up to $431.17million and $851.61million respectively.
DISCLAI ME R DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATER IALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.
We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the â€œSECâ€?) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who choosesto invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. ChartPoppers.com is a wholly-owned subsidiary of Seo Freisin, Inc.. While Seo Freisin has not been compensated for the distribution of this particular email, any future email regarding a specific company will be the result of an advertising and promotional campaign for which SeoFreisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. SeoFreisin and its affiliates currently hold no shares in the profiled company.
Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
Published on Jan 19, 2011
United Therapeutics Corporation (NASDAQ:UTHR) About United Therapeutics Corporation (NASDAQ:UTHR) United Therapeutics Corporation (NASDAQ:UT...